Table 1 The survey
Statement 1: Type of patients who can benefit from continuous glucose monitoring (flash and classic CGM) | |
1.1 1.2 1.3 1.4 1.5 1.6 | Based on the data available to date, continuous glucose monitoring can represent a valid prognostic tool in every person affected by diabetes mellitus Continuous glucose monitoring is prognostically useful in patients with type 1 diabetes and in patients with type 2 diabetes on multiple daily insulin injections Continuous glucose monitoring in type 2 diabetes treated with basal insulin and/or oral hypoglycaemic agents and/or other injecting drugs is useful in clinical characterization of the patient and in making treatment decisions (e.g., to monitor change of therapy) Continuous glucose monitoring is particularly useful in patients with physical limitations that prevent blood glucose measurement with the traditional capillary test (e.g., severe arthritis, Parkinson's disease, other) Continuous glucose monitoring is useful in patients in whom a rapid improvement in blood glucose control is clinically indicated (e.g., post-myocardial infarction, pre-/post-surgery, sepsis, acute respiratory failure, acute renal failure) Continuous glucose monitoring facilitates telemonitoring in elderly patients |
Statement 2: Prognostic impact of continuous glucose monitoring in diabetic patients affected by heart disease | |
2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 | The time-in-range (percentage of monitoring time with blood glucose values between 70 and 180 mg/dL) is a parameter that provides more complete and detailed information than HbA1c in the clinical evaluation of people with diabetes The reduction in hypoglycaemic episodes improves the prognosis of diabetic patients with ischemic heart disease The reduction of hyperglycaemic episodes improves the prognosis of diabetic patients with ischemic heart disease Time-in-range is an important element for therapeutic optimization in the diabetic patient with heart disease The time spent in hypoglycaemia is an important element for therapeutic optimization in the diabetic patient with heart disease Glycaemic variability is an important element for therapeutic optimization in the diabetic patient with heart disease Time-in-range has a prognostic role in the diabetic patient with heart failure Time spent in hypoglycaemia has a prognostic role in the diabetic patient with heart failure Glycaemic variability has a prognostic role in the diabetic patient with heart failure |
Statement 3: Use during acute cardiovascular events | |
3.1 3.2 3.3 3.4 | Continuous glucose monitoring can be easily used in coronary care unit/intensive care unit Reduction in hypoglycaemic episodes improves short-term prognosis during an acute cardiovascular event Reduction in hyperglycaemic episodes improves short-term prognosis in patients with an acute cardiovascular event The optimization of time-in-range and glycaemic variability and the reduction of time in hypoglycaemia are associated with an improvement in the long-term prognosis in patients with an acute cardiovascular event |
Statement 4: Insulin/hypoglycaemia education | |
4.1 4.2 4.3 | Continuous glucose monitoring helps patients with diabetes mellitus improve the perception of their disease Continuous glycaemic monitoring can be helpful in reducing hypoglycaemic episodes The possibility to use alarms, now available in all interstitial glucose sensors, helps prevent hypoglycaemias |